Cyclo Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference

Rhea-AI Summary

Cyclo Therapeutics (Nasdaq: CYTH) announced a live video webcast presentation on January 27, 2022, at 10:00 AM ET during the Virtual Investor 2022 Top Picks Conference. CEO N. Scott Fine will present followed by a moderated discussion and Q&A session, allowing live and pre-submitted questions from investors. A webcast replay will be available for one year after the event. Cyclo Therapeutics is focused on developing treatments for rare diseases, including Niemann-Pick Disease Type C, and is preparing for trials involving Alzheimer's Disease.

– Live video webcast presentation on Thursday, January 27^th at 10:00 AM ET

GAINESVILLE, Fla.--(BUSINESS WIRE)-- Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the Virtual Investor 2022 Top Picks Conference on Thursday, January 27, 2022 at 10:00 AM ET.

As part of the virtual event, the Company will provide a brief presentation, followed by a moderated discussion and an interactive Q&A session. In addition to the moderated portion of the event, all investors and interested parties will have the opportunity to submit questions live during the event. Interested parties may also pre-submit questions in advance of the live event, which can be sent via the conference website at virtualinvestorco.com. The Company will answer as many questions as possible during the event.

A live video webcast of the virtual event will be availability on the Events page of the Investors section of the Company’s website (cyclotherapeutics.com). A webcast replay will be available two hours following the live presentation and will be accessible for one year.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol^® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.gov NCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is planning an early phase clinical trial using Trappsol^® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol^® Cyclo™ are in development. For additional information, visit the Company’s website: www.cyclotherapeutics.com.

Safe Harbor Statement

This press release contains “forward-looking statements” about the company’s current expectations about future results, performance, prospects and opportunities, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company’s future performance include the company’s ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company’s biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company’s filings with the Securities and Exchange Commission, including, but not limited to, the company’s reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220120005409/en/

Investor Contact:

JTC Team, LLC

Jenene Thomas

(833) 475-8247

CYTH@jtcir.com

Source: Cyclo Therapeutics, Inc.

FAQ

When will Cyclo Therapeutics present at the Virtual Investor 2022 Top Picks Conference?

Cyclo Therapeutics will present on January 27, 2022, at 10:00 AM ET.

What is the stock symbol for Cyclo Therapeutics?

The stock symbol for Cyclo Therapeutics is CYTH.

Who is the CEO of Cyclo Therapeutics?

The CEO of Cyclo Therapeutics is N. Scott Fine.

What disease is Cyclo Therapeutics developing treatments for?

Cyclo Therapeutics is developing treatments for Niemann-Pick Disease Type C and Alzheimer's Disease.

Will there be a replay of Cyclo Therapeutics' presentation?

Yes, a webcast replay will be available two hours after the live presentation and accessible for one year.